Skip to main content

Table 3 Univariate survival analysis of prognostic factors of NSCLC (n = 42)

From: Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer

Variables

n

Median survival (95% CI) (days)

P

Age (years)

   

   <60

27

370.0 (301.3-438.7)

0.665

   ≥ 60

15

333.0 (244.6-421.4)

 

Stage

   

   III

23

416.0 (369.1-462.8)

0.163

   IV

19

327. 0 (298.7-355.3)

 

T factor

   

   T2-T3

17

431.0 (315.3-546.7)

0.051

   T4

25

348.0 (248.3-447.6)

 

N factor

   

   N0-N1

21

394.0 (312.2-475.8)

0.380

   N2-N3

21

348.0 (310.1-385.9)

 

ECOG

   

   1

30

403.0 (327.9-478.0)

0.130

   2-3

12

333.0 (311.5-354.5)

 

Histology

   

   SCC

31

367.0 (288.1-445.9)

0.270

   ADC

11

394.0 (324.8-463.1)

 

Smoking habit

   

   Smokers

36

370.0 (294.0-446.0)

0.745

   Non-smokers

06

367.0 (248.7-485.3)

 

Tobacco habit

   

   Yes

08

394.0 (352.3-435.6)

0.022

   No

34

314.0 (266.0-362.0)

 

Plasma VEGF (median)

   

   <275.2 pg/mL

21

348.0 (246.1-449.9)

0.885

   ≥ 275.2 pg/mL

21

370.0 (288.3-451.7)

 
  1. T, tumor; N, nodal status; ECOG, Eastern Cooperative Oncology Group; VEGF, vascular endothelial growth factor; 95% CI, 95% confidence interval.